GeneDx Holdings Corp

GeneDx Holdings Corp. is a patient centered health intelligence company. It engages in transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. The firm, through its Centrellis health intelligence platform, generates a more complete understanding of disease and wellness and provides science-driven solutions to the most pressing medical needs. The company was founded by Eric Schadt in October 2015 and is headquartered in Stamford, CT.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

GeneDx reports robust growth, eyes profitability by 2025

GeneDx's strong financial performance in 2022 and growth projections for 2023 indicate a promising trajectory for the company.
Strategic shifts towards whole genome sequencing, fundraising success, and favorable market coverage position GeneDx well for future success.
While facing challenges in business transitions and financial management, GeneDx has opportunities to drive profitability through margin expansion and strategic partnerships.

GeneDx reports robust Q1 earnings, eyes profitability by 2025

GeneDx's Q1 2023 performance reflects strong revenue growth and strategic positioning for future profitability by 2025.
The company's focus on rare disease testing, pediatric settings, and genome testing, coupled with financial improvements, highlights its resilience.
Challenges include managing cash burn, navigating competition, and balancing cost reduction with growth investments.
Opportunities for GeneDx include expanding market share, strategic partnerships, innovation in testing, and comprehensive patient care.

GeneDx reports record revenue and market dominance in genomics

GeneDx's strong performance in Q2 2023 reflects robust revenue growth and market dominance in exome and genome testing. The company's strategic focus on cost optimization, revenue enhancement, and market expansion positions it well for future profitability and growth.

GeneDx reports robust Q3 results, targets profitability by 2025

GeneDx Holdings Corp shows strong performance in Q3 2023 with revenue of $53 million and improved gross margins, supported by a cost reduction plan and debt facility.
While facing challenges in claim denials and lengthy appeal processes, the company aims to drive revenue growth from exome and genome testing to achieve profitability by 2025.
Opportunities lie in capital allocation for growth initiatives and sustainable profitability through cost reduction efforts and strategic investments in R&D.

GeneDx reports strong Q4 results, targets profitability by 2025

GeneDx demonstrated robust financial performance in Q4 2023, with revenue growth, improved margins, and reduced cash burn, setting a positive trajectory for future profitability.
Strategic initiatives like realigned sales strategy and focus on exome and genome tests position GeneDx for sustained growth and increased profitability in the coming years.
While challenges exist in managing cash burn and achieving profitability targets, GeneDx's strong financial position, strategic partnerships, and market focus offer opportunities for continued success.

GeneDx's strong financial performance, strategic strengths, and growth opportunities position it well for future success and profitability.
While facing challenges such as high denial rates and the path to profitability, the company's proactive approach and market focus offer avenues for improvement.
By leveraging its competitive advantages, addressing challenges, and capitalizing on growth opportunities, GeneDx aims to sustain its growth trajectory and achieve profitability by 2025.

GeneDx reports robust Q2 earnings, eyes profitability amid market expansion

GeneDx Holdings Corp's Q2 2024 performance reflects strong revenue growth, margin expansion, and progress towards profitability.
The company's strengths lie in its focus on pediatric genetics, successful product mix transition, and strategic investments in genome sequencing.
Challenges include policy expansion hurdles, maintaining financial discipline, and achieving profitability amidst industry dynamics.
Opportunities for GeneDx include market expansion through partnerships, patient access programs, and operational efficiency enhancements.

GeneDx reports robust Q3 earnings, eyes growth in genetic testing

GeneDx Holdings Corp delivered a strong Q3 performance, achieving profitability and raising revenue guidance for the year.
The company's strategic strengths lie in its market leadership, advanced sequencing capabilities, and diversified revenue streams.
While facing challenges in balancing growth and innovation, GeneDx has opportunities to expand into new markets and drive long-term success.
By optimizing costs, focusing on efficiency, and investing strategically, GeneDx aims to maintain profitability and drive innovation in genetic testing.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Management will host a conference call on Monday, April 29, 2024 to discuss first quarter 2024 financial and operating results at 4:30 p.m. Eastern Time.

GeneDx to Report First Quarter 2024 Financial Results on Monday, April 29, 2024

GENEDX HOLDINGS (WGS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Here's Why GENEDX HOLDINGS (WGS) Could be Great Choice for a Bottom Fisher

STAMFORD, Conn., March 14, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced its scientific contributions at the 2024 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting. Across one platform presentation, an industry symposium and six poster presentations, including one selected as a “Rapid Fire Poster Session,” an invitation-only presentation of the top 20 ACMG posters, GeneDx continues to demonstrate its industry leadership in shaping the future landscape of genomics.

GeneDx to Present Data at the 2024 American College of Medical Genetics (ACMG) Annual Meeting Demonstrating Clinical Superiority of its Exome, Paving the Way for the Future of Genomics

STAMFORD, Conn., Feb. 26, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that company management will participate in the Cowen Healthcare Conference from March 4-6 in Boston, MA.

GeneDx to Participate in 44th Annual Cowen Health Care Conference

GeneDx Holdings Corp. (WGS) Q4 2023 Earnings Call Transcript

Reported fourth quarter 2023 revenue from continuing operations 1 of $58.1M with more than 68% year-over-year growth of exome and genome test revenue Expanded fourth quarter 2023 adjusted gross margins 2 from continuing operations to 56% Narrowed fourth quarter 2023 adjusted net loss 2 to $17.8M and delivered 51% year-over-year cash burn reduction Issued guidance to deliver between $220M and $230M in FY 2024 revenue and reiterate path to profitability in 2025 GeneDx to host conference call today at 4:30 p.m. ET STAMFORD, Conn.

GeneDx Reports Fourth Quarter and Full Year 2023 Financial Results and Issues Guidance for Full Year 2024

GeneDx management will host a conference call at 4:30 p.m. Eastern Time on February 20, 2024 to discuss 2023 results and share full year 2024 guidance.

GeneDx to Report Fourth Quarter 2023 Financial Results on Tuesday, February 20, 2024

GeneDx Holdings Corp shares jumped 21% to $4.68 in late-morning trading on Tuesday after the provider of exome and genome testing and interpretation announced that it expects to exceed revised 2023 revenue guidance with fourth quarter 2023 revenue from continuing operations of more than $57 million.   GeneDx also said it expects at least 63% year-over-year growth from its exome and genome test revenue.

GeneDx Holdings stock climbs on upbeat 4Q guidance, profitability target

Expects to exceed revised 2023 revenue guidance with fourth quarter 2023 revenue from continuing operations1 of more than $57M with at least 63% year-over-year revenue growth for exome and genome test revenue Reduced fourth quarter 2023 cash burn 51% year-over-year and 21% sequentially Ending December 31, 2023 cash position of at least $131 million Reiterating the path to profitability in 2025 STAMFORD, Conn., Jan. 08, 2024 (GLOBE NEWSWIRE) -- GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today reported preliminary financial results for the fourth quarter and full year of 2023.

GeneDx Announces Preliminary 2023 Financial Results

New research from one of the largest exome sequencing studies of patients with epilepsy adds to the mounting evidence that exome sequencing offers superior clinical results compared to multi-gene panels New research from one of the largest exome sequencing studies of patients with epilepsy adds to the mounting evidence that exome sequencing offers superior clinical results compared to multi-gene panels

GeneDx Presents New Data at the American Epilepsy Society Annual Meeting Demonstrating That Exome Sequencing Outperforms Multi-Gene Panels for Patients with Epilepsy

STAMFORD, Conn., Nov. 28, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that company management will participate in the Evercore ISI HealthCONx Conference this week in Miami, FL.

GeneDx to Participate in 6th Annual Evercore ISI HealthCONx Conference

After losing some value lately, a hammer chart pattern has been formed for GeneDx Holdings Corp. (WGS), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Bears are Losing Control Over GeneDx Holdings Corp. (WGS), Here's Why It's a 'Buy' Now

GeneDx Holdings Corp. (NASDAQ:WGS ) Q3 2023 Results Conference Call October 30, 2023 4:30 PM ET Company Participants Sabrina Dunbar - Chief of Staff Katherine Stueland - President and CEO Kevin Feeley - CFO Conference Call Participants Joe Flanagan - Cowen Mark Massaro - BTIG Matt Kim - Jefferies Prashant Kota - Goldman Sachs Operator Good day, and thank you for standing by. Welcome to the GeneDx Third Quarter 2023 Earnings Conference Call.

GeneDx Holdings Corp. (WGS) Q3 2023 Earnings Call Transcript

Reported total revenue of $53M with more than 40% year-over-year growth of exome and genome test revenue

GeneDx Reports Third Quarter 2023 Financial Results and Business Highlights

STAMFORD, Conn., Oct. 09, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced it will release financial results for the third quarter of 2023 after the market closes on Monday, October 30, 2023. On the same day, Katherine Stueland, President and Chief Executive Officer of GeneDx, and Kevin Feeley, Chief Financial Officer of GeneDx, will host a conference call to discuss financial and operating results at 4:30 p.m. Eastern Time.

GeneDx to Report Third Quarter 2023 Financial Results on Monday, October 30, 2023

STAMFORD, Conn., Aug. 21, 2023 (GLOBE NEWSWIRE) -- GeneDx, a leader in delivering improved health outcomes through genomic and clinical insights, today announced that Genetics in Medicine, the official journal of the American College of Medical Genetics and Genomics (ACMG) has published a peer-reviewed research analysis resulting from a multi-lab collaboration involving GeneDx. The study, “The landscape of reported VUS in multi-gene panel and genomic testing: Time for a change,” evaluated the rate of inconclusive genetic variants, or variants of uncertain significance (VUS), reported with multi-gene panels versus exome and genome sequencing. Study findings concluded that VUS are reported more frequently on multi-gene panels (32.6%) than exome and genome sequencing (22.5%).

GeneDx Announces Data Demonstrating that Whole Exome and Genome Sequencing Report Fewer Variants of Uncertain Significance (VUS) than Multi-Gene Panel Testing Published in Genetics in Medicine

GeneDx Holdings Corp. (NASDAQ:WGS ) Q2 2023 Results Conference Call August 8, 2023 4:30 PM ET Company Participants Tricia Truehart - Head, IR Katherine Stueland - President and CEO Kevin Feeley - CFO Conference Call Participants Mark Massaro - BTIG Matt Kim - Jefferies Prashant Kota - Goldman Sachs Dan Brennan - Cowen Operator Good day, and thank you for standing by. Welcome to the GeneDx Second Quarter 2023 Earnings Conference Call.

GeneDx Holdings Corp. (WGS) Q2 2023 Earnings Call Transcript

Pacific Biosciences of California

Study is first of its kind to compare diagnostic rates across short- and long-read sequencing platforms  MENLO PARK, Calif. and STAMFORD, Conn.

PacBio and GeneDx Launch Research Collaboration with the University of Washington to Study Long-Read Whole Genome Sequencing for Increased Diagnostic Yield in Neonatal Care

Partnership allows commercial biopharma companies to leverage real-time data within comprehensive Prognos Marketplace to provide available treatment options for patients Partnership allows commercial biopharma companies to leverage real-time data within comprehensive Prognos Marketplace to provide available treatment options for patients

GeneDx and Prognos Health Announce Strategic Partnership to Help Rare Disease Patients More Rapidly Gain Access to Potential Treatment Options

STAMFORD, Conn., July 18, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced it will release financial results for the second quarter of 2023 after the market closes on Tuesday, August 8, 2023. On the same day, the management team from GeneDx will host a conference call to discuss financial and operating results at 4:30 p.m. Eastern Time.

GeneDx to Report Second Quarter 2023 Financial Results on Tuesday, August 8, 2023

STAMFORD, Conn., June 28, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced it will present new data on urine mitochondrial DNA testing at the 2023 United Mitochondrial Disease Foundation's (UMDF) Mitochondrial Medicine Symposium in Charlotte, North Carolina, June 28 - July 1, 2023.

GeneDx to Present New Data on Urine Mitochondrial DNA Testing at the 2023 United Mitochondrial Disease Foundation's Mitochondrial Medicine Symposium

N ew paper published today in Nature Methods describes the PanGenome Research-Tool Kit for analyz ing complex regions of the human pan genome

GeneDx Announces New Tool to Help Harness Human Pangenome Diversity for Clinical Interpretation of Variants

Eight state Medicaid programs now cover rWGS in the pediatric inpatient setting, with active bills in other states Eight state Medicaid programs now cover rWGS in the pediatric inpatient setting, with active bills in other states

GeneDx Commends the States of Arizona and Florida for Adding Rapid Whole Genome Sequencing (rWGS) as a Covered Benefit for Medicaid Pediatric Patients

Keynote session to highlight value of GeneDx genomic data and clinical insights to accelerate genetic neurodevelopmental disorder pipeline for Mahzi Therapeutics Keynote session to highlight value of GeneDx genomic data and clinical insights to accelerate genetic neurodevelopmental disorder pipeline for Mahzi Therapeutics

GeneDx to Participate in World Orphan Drug Congress Keynote and Panel Presentations

STAMFORD, Conn., May 22, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that it had received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) stating that, because the Company's Class A common stock had a closing bid price at or above $1.00 per share for a minimum of ten (10) consecutive business days, the Company had regained compliance with the minimum bid price requirement of $1.00 per share for continued listing on the Nasdaq Global Select Market, as set forth in Nasdaq Listing Rule 5450(a)(1), and that the matter is now closed.

News for GeneDx Holdings Corp Stock (WGS)